Forskolin

Forskolin__Adenylate cyclase activator SU 5402

Product Name Forskolin
Description

Adenylate cyclase activator

Purity >99%
CAS No. 66575-29-9
Molecular Formula C22H34O7
Molecular Weight 410.51
Storage Temperature -20ºC
Shipping Temperature Shipped Ambient
Product Type Activator
Solubility Soluble to 100 mM in DMSO, and to 10 mM in ethanol
Source Synthetic
Appearance White Solid
SMILES CC(=O)Oemail protected1email protected(C@@H2C@(email protected(CCC2(C)C)O)(C@@3(C@@1(OC@@(CC3=O)(C)C=C)C)O)C)O
InChI InChI=1S/C22H34O7/c1-8-19(5)11-14(25)22(27)20(6)13(24)9-10-18(3,4)16(20)15(26)17(28-12(2)23)21(22,7)29-19/h8,13,15-17,24,2
InChIKey OHCQJHSOBUTRHG-KGGHGJDLSA-N
Safety Phrases Classification: Caution: Substance not yet fully tested.
Safety Phrases:
S22 – Do not breathe dust
S24/25 – Avoid contact with skin and eyes
S36/37/39 – Wear suitable protective clothing, gloves and eye/face protection
Hazard Phrases:
H312
Precautionary Phrases:
P280
Cite This Product Forskolin (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-208)

References PubMed ID::http://www.ncbi.nlm.nih.gov/pubmed/19124664

Alternative Names (3R,4aR,5S,6S,6aS,10S,10aR,10bS)-6,10,10b-Trihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-3-vinyldodecahydro-1H-benzofchromen-5-yl acetate
Research Areas Cancer, Apoptosis
PubChem ID 47936
Scientific Background Forskolin resensitizes cell receptors by activating adenyl cyclase, and increasing the intracellular levels of cAMP (1). Medically forskolin provides a route to inhibition of colon cancer cell growth and survival (2). It is also a vasodilator, may be helpful in controlling the cause of glaucoma (3), reduces urinary tract infections, and may help to increase the skin’s natural resistance to burning under UV light (1).
References 1. Passeron T., Namiki T., Passeron H.J., Le Pape E., and Hearing V.J. (2009) J Invest Dermatol. 129(1): 162-166.
2. McEwan D.G., Brunton V.G., Baillie G.S., Leslie N.R., Houslay M.D., and Frame M.C. (2007) Cancer Research. 67(11).
3. Pescosolido N., and Librando A. (2010) Clin Ter. 161(3): e81-5.